Andrea Wang-Gillam, MD, PhD, discusses a trial looking at PF-04136309, an investigational chemokine receptor antagonist, in combination with FOLFIRINOX for the treatment of locally advanced pancreatic cancer.
Andrea Wang-Gillam, MD, PhD, assistant professor, Department of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, discusses a trial looking at PF-04136309, an investigational chemokine receptor antagonist, in combination with FOLFIRINOX for the treatment of locally advanced pancreatic cancer.
More on this trial > >
<<<
Back to the Gastrointestinal Cancers Symposium conference page
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More